Xilio Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 73
- Market Cap
- $39.9M
- Website
- http://www.xiliotx.com
- Introduction
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Cancer Stocks in the Spotlight: The Immunotherapy Revolution
Immunotherapy is revolutionizing cancer treatment by using the body's immune system to precisely target and destroy cancer cells, offering hope and reshaping healthcare. With a 100% success rate in some trials and the global cancer immunotherapy market projected to reach $258 billion by 2031, it presents unprecedented opportunities for investors.
© Copyright 2025. All Rights Reserved by MedPath